[HTML][HTML] Carbamazepine therapy and HLA genotype
L Dean - 2018 - europepmc.org
Carbamazepine (brand names include Carbatrol, Epitol, Equetro, and Tegretol) is an
effective antiseizure drug that is often used as a first-line agent in the treatment of epilepsy …
effective antiseizure drug that is often used as a first-line agent in the treatment of epilepsy …
[HTML][HTML] Amitriptyline therapy and CYP2D6 and CYP2C19 genotype
L Dean - 2017 - europepmc.org
Amitriptyline is a tricyclic antidepressant used in the treatment of several psychiatric
disorders, including major depression, obsessive-compulsive disorder, panic attacks …
disorders, including major depression, obsessive-compulsive disorder, panic attacks …
Antidepressant pharmacogenetics in children and young adults: A systematic review
A Al Maruf, A Greenslade, PD Arnold… - Journal of Affective …, 2019 - Elsevier
Objective Antidepressants are frequently prescribed and are the first-line pharmacological
treatments for psychiatric disorders in children and adolescents. Although antidepressants …
treatments for psychiatric disorders in children and adolescents. Although antidepressants …
The challenges of implementing pharmacogenomic testing in the clinic
AM Moyer, PJ Caraballo - Expert Review of Pharmacoeconomics …, 2017 - Taylor & Francis
Introduction: Pharmacogenomic testing has the potential to greatly benefit patients by
enabling personalization of medication management, ensuring better efficacy and …
enabling personalization of medication management, ensuring better efficacy and …
Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5
Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics
of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways …
of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways …
Phenotyping of human CYP450 enzymes by endobiotics: current knowledge and methodological approaches
Drug response is subject to an important within-and between-individual variability owing,
mainly, to pharmacokinetic and pharmacodynamic factors. Pharmacokinetics includes …
mainly, to pharmacokinetic and pharmacodynamic factors. Pharmacokinetics includes …
Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC–MS for investigating the …
M Zhao, J Tao, D Qian, P Liu, E Shang, S Jiang… - … of Chromatography B, 2016 - Elsevier
A sensitive and rapid method for determination of loganin, morroniside, catalpol and
acteoside in rat plasma after oral administration of Rehmannia glutinosa Libosch and …
acteoside in rat plasma after oral administration of Rehmannia glutinosa Libosch and …
Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype–phenotype translation
T Frederiksen - Basic & Clinical Pharmacology & Toxicology, 2023 - Wiley Online Library
Abstract Cytochrome P450 2D6 (CYP2D6) is an important drug‐metabolizing enzyme
exhibiting extensive interindividual variability predominantly caused by genetic …
exhibiting extensive interindividual variability predominantly caused by genetic …
Novel independent trans-and Cis-genetic variants associated with CYP2D6 expression and activity in human livers
Cytochrome P450 2D6 (CYP2D6) is a critical hepatic drug-metabolizing enzyme in humans,
responsible for metabolizing approximately 20%–25% of commonly used medications such …
responsible for metabolizing approximately 20%–25% of commonly used medications such …
Quantifying the impact of phenoconversion on medications with actionable pharmacogenomic guideline recommendations in an acute aged persons mental health …
S Mostafa, TM Polasek, LJ Sheffield, D Huppert… - Frontiers in …, 2021 - frontiersin.org
Introduction: Polypharmacy and genetic variants that strongly influence medication response
(pharmacogenomics, PGx) are two well-described risk factors for adverse drug reactions …
(pharmacogenomics, PGx) are two well-described risk factors for adverse drug reactions …